

Media release

## **DKSH and Lotus give patients with Parkinson's disease access to high-quality medicine in the Philippines**

**Following the success of its expansion in Singapore, DKSH has signed an exclusive partnership agreement with Lotus in the Philippines to ensure sustainable growth across APAC.**

Manila, December 1, 2020 – DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow in Asia and beyond, and Lotus, a preferred global specialty generic partner, have announced their strategic partnership to expand Lotus' pharma business into the Philippines. This collaboration will provide DKSH the exclusive rights to market Lotus' treatment for Parkinson's disease, Stalevo®, in the Philippines.

Further to the cooperation with Lotus for Singapore during 2018 and 2019 with successful growth, the extension of this partnership to the Philippines, specifically for its Parkinson's treatment, emphasizes DKSH's capability to enrich people's lives and increase market share thanks to an extensive network of hospitals, clinics and pharmacies across the region. This collaboration complies with DKSH's strategic direction of strengthening its regional footprint in the Philippines.

Petar Vazharov, Chief Executive Officer of Lotus, commented: "As being strongly committed to making a difference for our patients, we are pleased to have DKSH as our strategic partner to ensure our Parkinson's products are accessible to patients across APAC. The market expansion into the Philippines will not just benefit us and DKSH, but also the patients in the country who suffer from Parkinson's disease for tremor, muscle stiffness, slowness and poor movement and control."

Dr. Varun Sethi, Vice President, Healthcare, DKSH Southeast Asia and Vietnam, said: "Our vision is to enrich people's lives. We provide the best possible commercial outsourcing service to our clients, so that they, in turn, can focus on their core competencies in developing excellent products to improve the lives of patients. We are thrilled to support Lotus in expanding their market presence to the Philippines. Through our extensive networks of hospitals, clinics and pharmacies, we will grow Lotus' visibility and its product portfolio will help a lot of Filipino patients with Parkinson's disease."

### **About Lotus**

Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

### **About DKSH**

DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps companies to grow across the Business Units Healthcare, Consumer Goods, Performance Materials and Technology. The service portfolio covers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 36 markets with 33,350 specialists, generating net sales of CHF 11.6 billion in 2019. With its Swiss heritage, DKSH has been deeply rooted in Asia Pacific since 1865. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 8,220 specialists, the Business Unit generated net sales of CHF 6.0 billion in 2019.

**For further information, please contact:**

**DKSH Business Unit Healthcare**

Sheena Flannery

Director, Group Communications

+66 2 220 9739

[sheena.flannery@dksh.com](mailto:sheena.flannery@dksh.com)